FDA WARNING_LETTER - Cellular Rx Inc - April 30, 2011
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On April 2011, the FDA reviewed the website www.cellpro7.com and determined that the product Cell Pro 7 is promoted for conditions that cause it to be a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)]. The therapeutic claims on the website, including "Arthritis, joint and muscle pain relief," "Migraine... and Allergy headache relief," and "Asthma, COPD, bronchial infection relief," establish the product as a drug intended for the cure, mitigation, treatment, or prevention of disease. The website also features testimonials claiming relief from arthritis, depression, allergies, severe burns, cluster headaches, and a reduction in PSA levels. Additionally, the Facebook account http://www.facebook.com/pages/Cell-Pro7/351345481336 contains testimonials making disease claims, such as controlling osteoarthritis, diabetes, and blood pressure.
The FDA states that Cell Pro 7 is not generally recognized as safe and effective for these uses, making it a "new drug" under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs require prior FDA approval under section 505(a) [21 U.S
ID · 69520e97-2647-43ea-8286-f6cca6b6ebbf
Full citation text and observation details available on the Dashboard.